TCI Wealth Advisors’s Viridian Therapeutics VRDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-132
Closed -$3.36K 2183
2023
Q1
$3.36K Buy
+132
New +$4.23K ﹤0.01% 1788

Other funds holding VRDN

TCI Wealth Advisors's VRDN Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Viridian Therapeutics (VRDN) in Q2 2023, closing a stake of 132 shares — an estimated $3.36K sold.

TCI Wealth Advisors first reported a position in VRDN in Q1 2023 and held it in 1 quarter. The position peaked at $3.36K in Q1 2023. 128 funds tracked by Wall St. Rank hold VRDN as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Viridian Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 132 Viridian Therapeutics shares in Q2 2023, an estimated $3.36K.
  • TCI Wealth Advisors first reported a position in Viridian Therapeutics in Q1 2023 and held it in 1 quarter.
  • TCI Wealth Advisors's Viridian Therapeutics position peaked at $3.36K in Q1 2023.
  • 128 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.